ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc (MIRM)

39.35
1.45
(3.83%)
At close: September 19 4:00PM
39.35
0.00
( 0.00% )
After Hours: 4:43PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
39.35
Bid
36.32
Ask
40.00
Volume
338,897
38.31 Day's Range 40.17
23.14 52 Week Range 45.23
Market Cap
Previous Close
37.90
Open
38.57
Last Trade
5
@
39.45
Last Trade Time
17:12:06
Financial Volume
$ 13,300,554
VWAP
39.2466
Average Volume (3m)
587,831
Shares Outstanding
47,707,204
Dividend Yield
-
PE Ratio
-11.49
Earnings Per Share (EPS)
-3.43
Revenue
186.37M
Net Profit
-163.42M

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-
Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MIRM. The last closing price for Mirum Pharmaceuticals was $37.90. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of $ 23.14 to $ 45.23.

Mirum Pharmaceuticals currently has 47,707,204 shares outstanding. The market capitalization of Mirum Pharmaceuticals is $1.81 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.49.

Mirum Pharmaceuticals (MIRM) Options Flow Summary

Overall Flow

Bearish

Net Premium

-40k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

MIRM Latest News

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on September 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 9, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC...

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum will also host a conference call to discuss the...

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI® (maralixibat) oral solution for the...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Approbation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFIC

La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de trois mois et plus. L’approbation fait suite à l’avis...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.46-5.8837598660641.8141.9636.859152650339.11626686CS
4-2.13-5.135004821641.4845.2336.859139624441.10951671CS
126.4919.75045648232.8645.2332.4758783139.44181688CS
2612.7447.876738068426.6145.2323.1459909032.79575522CS
527.122.01550387632.2545.2323.1458969231.10469962CS
15621.11115.73464912318.2445.2312.8243070026.96013278CS
26029.96319.0628328019.3945.236.512631446325.34519873CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LFLYLeafly Holdings Inc
$ 3.76
(110.06%)
4.54M
AENTAlliance Entertainment Holding Corporation
$ 2.84
(39.22%)
121.18k
AGBAAGBA Group Holding Ltd
$ 2.75
(30.33%)
1.15M
TNONTenon Medical Inc
$ 6.40
(27.24%)
2.52M
AEMDAethlon Medical Inc
$ 0.4937
(26.59%)
8.3M
EJHE Home Household Service Holdings Ltd
$ 0.0752
(-22.95%)
8.47M
KOPNKopin Corporation
$ 0.819
(-15.05%)
188.93k
NCINeo Concept International Group Holdings Ltd
$ 0.725
(-13.69%)
1.52M
VEROVenus Concept Inc
$ 0.7602
(-11.60%)
436.33k
MYNAMynaric AG
$ 1.1602
(-9.36%)
108.05k
EJHE Home Household Service Holdings Ltd
$ 0.0752
(-22.95%)
8.47M
AEMDAethlon Medical Inc
$ 0.4937
(26.59%)
8.3M
HSTHost Hotels and Resorts Inc
$ 18.53
(0.00%)
6.45M
LFLYLeafly Holdings Inc
$ 3.76
(110.06%)
4.54M
SQQQProShares UltraPro Short QQQ
$ 7.78
(0.26%)
4.25M

Your Recent History

Delayed Upgrade Clock